Cited by 1,558SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Spike mutation D614G alters SARS-CoV-2 fitness

Open access

Plante, Jessica A., Liu, Yang, Liu, Jianying, Xia, Hongjie, Johnson, Bryan A., Lokugamage, Kumari G., Zhang, Xianwen, Muruato, Antonio E., Zou, Jing, Fontes-Garfias, Camila R., Mirchandani, Divya, Scharton, Dionna, Bilello, John P., Ku, Zhiqiang, An, Zhiqiang, Kalveram, Birte, Freiberg, Alexander N., Menachery, Vineet D., Xie, Xuping, Plante, Kenneth S., Weaver, Scott C., Shi, Pei-Yong·2021·Nature

DOI 10.1038/s41586-020-2895-3PMC PMC8158177

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein substitution D614G became dominant during the coronavirus disease 2019 (COVID-19) pandemic 1,2. However, the effect of this variant on viral spread and vaccine efficacy remains to be defined. Here we engineered the spike D614G substitution in the USA-WA1/2020 SARS-CoV-2 strain, and found that it enhances viral replication in human lung epithelial cells and primary human airway tissues by increasing the infectivity and stability of virions. Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs, supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission. Sera from hamsters infected with D614 virus exhibit modestly higher neutralization titres against G614 virus than against D614 virus, suggesting that the mutation is unlikely to reduce the ability of vaccines in clinical trials to protect against COVID-19, and that therapeutic antibodies should be tested against the circulating G614 virus. Together with clinical findings, our work underscores the importance of this variant in viral spread and its implications for vaccine efficacy and antibody therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-020-2895-3

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
The New Statistics: Why and How
Cumming, G. (2014) · Psychological Science · doi:10.1177/0956797613504966 · Cited by 3,200
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes
HCA Lung Biological Network, Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-López, C., Maatz, H., Reichart, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0868-6 · Cited by 2,501
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
Hoffmann, M., Kleine-Weber, H., & Pöhlmann, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.022 · Cited by 1,852
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Self-citation
SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract
Hou, Y. J., Okuda, K., Edwards, C. E., Martinez, D. R., Asakura, T., Dinnon, K. H., Kato, T., Lee, R. E., Yount, B. L., Mascenik, T. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.042 · Cited by 1,488

Show all 37 references

Research works printed but not linked: 1

Mulligan, M. J. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589–593 (2020). · DOI · Paper page

Sorted by citations

Items 701–800 of 1,008

An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection
Safarchi, A., Fatima, S., Ayati, Z., & Vafaee, F. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00674-6 · Cited by 16
High Rate of Mutational Events in SARS-CoV-2 Genomes across Brazilian Geographical Regions, February 2020 to June 2021
de Souza, U. J. B., dos Santos, R. N., Campos, F. S., Lourenço, K. L., da Fonseca, F. G., Spilki, F. R., & Corona-ômica.BR/MCTI Network (2021) · Viruses · doi:10.3390/v13091806 · Cited by 16
One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization
Gu, M., Torres, J. L., Li, Y., Ry, A. V., Greenhouse, J. J., Wallace, S. M., Chiang, C.-I., Pessaint, L., Jackson, A. M., Porto, M., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1994354 · Cited by 16
Establishment of a pseudovirus neutralization assay based on SARS-CoV-2 S protein incorporated into lentiviral particles
Wang, S., Liu, L., Wang, C., Wang, Z., Duan, X., Chen, G., Zhou, H., & Shao, H. (2022) · Biosafety and Health · doi:10.1016/j.bsheal.2021.12.006 · Cited by 16
Source terms for benchmarking models of SARS-CoV-2 transmission via aerosols and droplets
Stettler, M. E. J., Nishida, R. T., de Oliveira, P. M., Mesquita, L. C. C., Johnson, T. J., Galea, E. R., Grandison, A., Ewer, J., Carruthers, D. J., Sykes, D., et al. (2022) · Royal Society Open Science · doi:10.1098/rsos.212022 · Cited by 17
mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
Darling, T. L., Ying, B., Whitener, B. M., VanBlargan, L. A., Bricker, T. L., Liang, C.-Y., Joshi, A., Bamunuarachchi, G., Seehra, K., Schmitz, A. J., et al. (2022) · Med · doi:10.1016/j.medj.2022.03.009 · Cited by 15
Engineering viral genomics and nano-liposomes in microfluidic platforms for patient-specific analysis of SARS-CoV-2 variants
Satta, S., Shahabipour, F., Gao, W. F., Lentz, S. R., Perlman, S. M., Ashammakhi, N. A., & Hsiai, T. K. (2022) · Theranostics · doi:10.7150/thno.72339 · Cited by 16
De novo emergence of SARS‐CoV‐2 spike mutations in immunosuppressed patients
Simons, L. M., Ozer, E. A., Gambut, S., Dean, T. J., Zhang, L., Bhimalli, P. P., Schneider, J. R., Mamede, J. I., Ison, M. G., Karmali, R., et al. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13914 · Cited by 16
Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type
Dingemans, J., van der Veer, B. M. J. W., Gorgels, K. M. F., Hackert, V., Hensels, A. Y. J., den Heijer, C. D. J., Hoebe, C. J. P. A., Savelkoul, P. H. M., & van Alphen, L. B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1027271 · Cited by 19
Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19
Yakoubi, A., & Dhafer, C. E. B. (2022) · Plasmonics · doi:10.1007/s11468-022-01754-0 · Cited by 16
SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters 1
Zhou, B., Zhou, R., Chan, J. F., Zeng, J., Zhang, Q., Yuan, S., Liu, L., Robinot, R., Shan, S., Liu, N., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2245921 · Cited by 22
Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2
Xie, J., Ding, C., He, J., Zhang, Y., Ni, S., Zhang, X., Chen, Q., Wang, J., Huang, L., He, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.715464 · Cited by 16
Self-citation
Local emergence and decline of a SARS-CoV-2 variant with mutations L452R and N501Y in the spike proteinPreprint
Mallm, J., Bundschuh, C., Kim, H., Weidner, N., Steiger, S., Lander, I., Börner, K., Bauer, K., Hübschmann, D., Beneš, V., et al. (2021) · medRxiv · doi:10.1101/2021.04.27.21254849 · Cited by 16
A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CL(pro) inhibitor PF-00835231 as a potential new treatment for COVID-19Preprint
de Vries, M., Mohamed, A., Prescott, R. A., Valero-Jimenez, A. M., Desvignes, L., O’Connor, R., Steppan, C. M., Devlin, J. C., Ivanova, E. N., Herrera, A. M., et al. (2021) · PubMed Central · doi:10.1101/2020.08.28.272880 · Cited by 14
Chemical tools for discriminating single nucleotide variants: from design principles to clinical applications
Huang, D., Liu, Y., Wang, G. A., Lv, S., Tan, Y., & Li, F. (2025) · Chemical Society Reviews · doi:10.1039/d5cs01006c · Cited by 17
Self-citation
Analysis of SARS-COV2 spike protein variants among Iraqi isolates
Sabir, D. K. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101420 · Cited by 15
Progress in the Diagnosis and Treatment of COVID-19 in Children: A Review
Wang, L., Li, G., Yuan, C., Yang, Y., Ling, G., Zheng, J., Zhou, Y., Zhang, T., Lin, W., & Lin, Z. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s335888 · Cited by 15
SARS-CoV-2 Variants: Mutations and Effective Changes
Park, G., & Hwang, B. H. (2021) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-021-0327-3 · Cited by 17
The dynamics of circulating SARS-CoV-2 lineages in Bogor and surrounding areas reflect variant shifting during the first and second waves of COVID-19 in Indonesia
Prasetyoputri, A., Dharmayanthi, A. B., Iryanto, S. B., Andriani, A., Nuryana, I., Wardiana, A., Ridwanuloh, A. M., Swasthikawati, S., Hariyatun, H., Nugroho, H. A., et al. (2022) · PeerJ · doi:10.7717/peerj.13132 · Cited by 15
Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination – kinetics of plasma antibodies, plasmablasts and memory B cells
Wietschel, K. A., Fechtner, K., Antileo, E., Abdurrahman, G., Drechsler, C. A., Makuvise, M. K., Rose, R., Voß, M., Krumbholz, A., Michalik, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1382911 · Cited by 15
Beyond COVID-19: the promise of next-generation coronavirus vaccines
Mukesh, R. K., Yinda, C. K., Munster, V. J., & van Doremalen, N. (2024) · npj Viruses · doi:10.1038/s44298-024-00043-3 · Cited by 15
Making sense of spike D614G in SARS-CoV-2 transmission
Shi, A. C., & Xie, X. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1893-9 · Cited by 15
Self-citation
Neutral evolution test of the spike protein of SARS-CoV-2 and its implications in the binding to ACE2
López-Cortés, G. I., Palacios-Pérez, M., Zamudio, G. S., Veledíaz, H. F., Ortega, E., & José, M. V. (2021) · Scientific Reports · doi:10.1038/s41598-021-96950-z · Cited by 15
A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic
Chrysostomou, A. C., Vrancken, B., Koumbaris, G., Themistokleous, G., Aristokleous, A., Masia, C., Eleftheriou, C., Iοannou, C., Stylianou, D. C., Ioannides, M., et al. (2021) · Viruses · doi:10.3390/v13061098 · Cited by 15
Molecular Diagnosis of SARS-CoV-2: Assessing and Interpreting Nucleic Acid and Antigen Tests
Zimmerman, P. A., King, C. L., Ghannoum, M. A., Bonomo, R. A., & Procop, G. W. (2021) · Pathogens and Immunity · doi:10.20411/pai.v6i1.422 · Cited by 15
Detection of SARS-CoV-2 spike protein D614G mutation by qPCR-HRM analysis
Gazali, F. M., Nuhamunada, M., Nabilla, R., Supriyati, E., Hakim, M. S., Arguni, E., Daniwijaya, E. W., Nuryastuti, T., Haryana, S. M., Wibawa, T., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e07936 · Cited by 15
Clinical, Virological, Immunological, and Genomic Characterization of Asymptomatic and Symptomatic Cases With SARS-CoV-2 Infection in India
Chatterjee, S., Datey, A., Sengupta, S., Ghosh, A., Jha, A., Walia, S., Singh, S., Suranjika, S., Bhattacharya, G., Laha, E., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.725035 · Cited by 15
Whole genome sequence analysis showing unique SARS-CoV-2 lineages of B.1.524 and AU.2 in Malaysia
Zainulabid, U. A., Yassim, A. S. M., Hussain, M., Aslam, A., Soffian, S. N., Ibrahim, M. S. M., Kamarudin, N., Kamarulzaman, M. N., Hin, H. S., & Ahmad, H. F. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263678 · Cited by 15
Mathematical Modeling of SARS-CoV-2 Omicron Wave under Vaccination Effects
González‐Parra, G., & Arenas, A. J. (2023) · Computation · doi:10.3390/computation11020036 · Cited by 16
SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavagePreprint
Escalera, A., Gonzalez-Reiche, A. S., Aslam, S., Mena, I., Pearl, R. L., Laporte, M., Fossati, A., Rathnasinghe, R., Alshammary, H., van de Guchte, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.05.455290 · Cited by 15
Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccinePreprint
Xia, H., Zou, J., Kurhade, C., Cai, H., Yang, Q., Cutler, M. W., Cooper, D., Muik, A., Jansen, K. U., Xie, X., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.21.476344 · Cited by 15
Self-citation
A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamstersPreprint
Ying, B., Darling, T. L., Desai, P., Liang, C.-Y., Dmitriev, I. P., Soudani, N., Bricker, T. L., Kashentseva, E. A., Harastani, H., Schmidt, A. G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.04.539332 · Cited by 13
COVID-19: Myths and Reality
Kordyukova, L. V., & Shanko, A. V. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921070026 · Cited by 13
Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity
Tang, H., Gao, L., Wu, Z., Meng, F., Zhao, X., Shao, Y., Shi, X., Qiao, S., An, J., Du, X., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.720357 · Cited by 15
Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa
Okoh, O. S., Nii-Trebi, N. I., Jakkari, A., Olaniran, T. T., Senbadejo, T. Y., Kafintu-kwashie, A. A., Dairo, E. O., Ganiyu, T. O., Akaninyene, I. E., Ezediuno, L. O., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103880 · Cited by 13
Landscape-Based Protein Stability Analysis and Network Modeling of Multiple Conformational States of the SARS-CoV-2 Spike D614G Mutant: Conformational Plasticity and Frustration-Induced Allostery as Energetic Drivers of Highly Transmissible Spike Variants
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00124 · Cited by 16
The Potential Roles of BCG Vaccine in the Prevention or Treatment of COVID-19
Wang, J., Zhang, Q., Wang, H., & Gong, W. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2705157 · Cited by 14
Differences in New Variant of Concern Replication at Physiological Temperatures In Vitro
Stauft, C. B., Sangare, K., & Wang, T. T. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac264 · Cited by 14
Astersaponin I from Aster koraiensis is a natural viral fusion blocker that inhibits the infection of SARS-CoV-2 variants and syncytium formation
Kim, T., Kim, J.-Y., Kwon, H., Jeon, S., Lee, S. J., Jung, H.-S., Kim, S.-H., Jang, D., & Lee, C. J. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105428 · Cited by 11
Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform
Kipfer, E. T., Hauser, D., Lett, M. J., Otte, F., Urda, L., Zhang, Y., Lang, C. M. R., Chami, M., Mittelholzer, C., & Klimkait, T. (2023) · eLife · doi:10.7554/elife.89035 · Cited by 14
Some common deleterious mutations are shared in SARS-CoV-2 genomes from deceased COVID-19 patients across continents
Islam, M. A., Marzan, A. A., Arman, M. S., Shahi, S., Sakif, T. I., Hossain, M., Islam, T., & Hoque, M. N. (2023) · Scientific Reports · doi:10.1038/s41598-023-45517-1 · Cited by 18
Natural products as a source of Coronavirus entry inhibitors
Szabó, D., Crowe, A. P., Mamotte, C. D. S., & Strappe, P. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1353971 · Cited by 14
SARS-CoV-2 outbreak: role of viral proteins and genomic diversity in virus infection and COVID-19 progression
Hussein, H. A. M., Thabet, A. A., Wardany, A. A., El-Adly, A. M., Ali, M. E., Hassan, M. E. A., Abdeldayem, M. A. B., Mohamed, A.-R. M. A., Sobhy, A., El‐Mokhtar, M. A., et al. (2024) · Virology Journal · doi:10.1186/s12985-024-02342-w · Cited by 17
Current Updates on Variants of SARS‐CoV‐ 2: Systematic Review
Erkihun, M., Ayele, B., Asmare, Z., & Endalamaw, K. (2024) · Health Science Reports · doi:10.1002/hsr2.70166 · Cited by 16
Long COVID across SARS‐CoV‐2 variants: Clinical features, pathogenesis, and future directions
Lok, L. S. C., Sarkar, S., Lam, C. C. I., Law, C., Chau, S. T., Leung, C. Y. T., Cheang, W. H., Li, T., Monteiro, O., & Baptista‐Hon, D. T. (2024) · MedComm – Future Medicine · doi:10.1002/mef2.70004 · Cited by 16
Are the emerging SARS-COV-2 mutations friend or foe?
Erol, A. (2021) · Immunology Letters · doi:10.1016/j.imlet.2020.12.014 · Cited by 14
Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques
Rosati, M., Agarwal, M., Hu, X., Devasundaram, S., Stellas, D., Chowdhury, B., Bear, J., Burns, R., Donohue, D. E., Pessaint, L., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009701 · Cited by 14
A comprehensive review of the analysis and integration of omics data for SARS-CoV-2 and COVID-19
Zhu, Z., Zhang, S., Wang, P., Chen, X., Bi, J., Cheng, L., & Zhang, X. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab446 · Cited by 14
Self-citation
A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
Brinkkemper, M., Brouwer, P. J. M., Maisonnasse, P., Grobben, M., Caniels, T. G., Poniman, M., Burger, J. A., Bontjer, I., Oomen, M., Bouhuijs, J. H., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00411-7 · Cited by 15
In Silico Screening of Potential Phytocompounds from Several Herbs against SARS-CoV-2 Indian Delta Variant B.1.617.2 to Inhibit the Spike Glycoprotein Trimer
Bharathi, M., Sivamaruthi, B. S., Kesika, P., Thangaleela, S., & Chaiyasut, C. (2022) · Applied Sciences · doi:10.3390/app12020665 · Cited by 15
Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes
Qian, Z., Li, P., Tang, X., & Lü, J. (2022) · Medical Review · doi:10.1515/mr-2021-0035 · Cited by 14
Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives
Khairnar, P., Soni, M., Handa, M., Riadi, Y., Kesharwani, P., & Shukla, R. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2056187 · Cited by 15
A short plus long-amplicon based sequencing approach improves genomic coverage and variant detection in the SARS-CoV-2 genome
Arana, C., Liang, C., Brock, M., Zhang, B., Zhou, J., Chen, L., Cantarel, B. L., SoRelle, J. A., Hooper, L. V., & Raj, P. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261014 · Cited by 17
Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants
Hu, Y., Hu, J., Gong, H., Danchin, A., Sun, R., Chu, H., Hung, I. F., Yuen, K., To, K. K., Zhang, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861050 · Cited by 15
The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition
Qiao, S., Zhang, S., Ge, J., & Wang, X. (2022) · FEBS Open Bio · doi:10.1002/2211-5463.13454 · Cited by 16
The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2
Aliyari, S. R., Quanquin, N. M., Pernet, O., Zhang, S., Wang, L., & Cheng, G. (2022) · Pathogens · doi:10.3390/pathogens11050538 · Cited by 17
An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose
Nag, K., Chandra Baray, J., Rahman Khan, M., Mahmud, A., Islam, J., Myti, S., Ali, R., Haq Sarker, E., Kumar, S., Hossain Chowdhury, M., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.035 · Cited by 13
Germinal center–mediated broadening of B cell responses to SARS-CoV-2 booster immunization
Malladi, S. K., Jaiswal, D., Ying, B., Alsoussi, W. B., Darling, T. L., Dadonaite, B., Civljak, A., Horvath, S. C., Zhou, J. Q., Kim, W., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adu4107 · Cited by 15
Characterization of SARS-CoV-2 East Java isolate, Indonesia
Rantam, F. A., Prakoeswa, C. R. S., Tinduh, D., Nugraha, J., Susilowati, H., Wijaya, A. Y., Puspaningsih, N. N. T., Puspitasari, D., Husada, D., Kurniati, N. D., et al. (2021) · F1000Research · doi:10.12688/f1000research.53137.1 · Cited by 12
Potent inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 by photosensitizers compounds
Yu, S., Sun, G., Sui, Y., Li, H., Mai, Y., Wang, G., Zhang, N., Bi, Y., Gao, G. F., Xu, P., et al. (2021) · Dyes and Pigments · doi:10.1016/j.dyepig.2021.109570 · Cited by 13
Frustration-driven allosteric regulation and signal transmission in the SARS-CoV-2 spike omicron trimer structures: a crosstalk of the omicron mutation sites allosterically regulates tradeoffs of protein stability and conformational adaptability
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp01893d · Cited by 12
COVID’s future: Viral multi-lineage evolution and the dynamics of small epidemic waves without seasonality in COVID-19
Sun, Y., Wang, M., Wei, F., Huang, S.-Z., & Xu, J. (2023) · Journal of Biosafety and Biosecurity · doi:10.1016/j.jobb.2023.07.003 · Cited by 13
High-resolution and real-time wastewater viral surveillance by Nanopore sequencing
Xu, X., Deng, Y., Ding, J., Tang, Q., Lin, Y., Zheng, X., & Zhang, T. (2024) · Water Research · doi:10.1016/j.watres.2024.121623 · Cited by 13
Whole genome analysis of more than 10 000 SARS-CoV-2 virus unveils global genetic diversity and target region of NSP6
Saha, I., Ghosh, N., Pradhan, A., Sharma, N., Maity, D., & Mitra, K. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab025 · Cited by 13
Is increased mortality by multiple exposures to COVID-19 an overseen factor when aiming for herd immunity?
Helle, K. B., Sadiku, A., Zelleke, G. M., Bouba, A., Ibrahim, T. B., Obama, H. C. J. T., Appiah, V., Ngwa, G. A., Teboh-Ewungkem, M. I., & Schneider, K. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253758 · Cited by 12
Phylogenomic analysis of SARS-CoV-2 from third wave clusters in Malaysia reveals dominant local lineage B.1.524 and persistent spike mutation A701V
Suppiah, J. (2021) · Tropical biomedicine · doi:10.47665/tb.38.3.070 · Cited by 13
Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models
Kim, Y., Casel, M. A. B., & Choi, Y. K. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-2033-z · Cited by 14
Evolutionary Traits and Genomic Surveillance of SARS-CoV-2 in South America
Ortíz-Pineda, P. A., & Sierra-Torres, C. H. (2022) · Global Health · doi:10.1155/2022/8551576 · Cited by 13
Deep phylogenetic-based clustering analysis uncovers new and shared mutations in SARS-CoV-2 variants as a result of directional and convergent evolution
Nunes, D. R., Braconi, C. T., Ludwig‐Begall, L. F., Arns, C. W., & Durães‐Carvalho, R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268389 · Cited by 14
Conformational stability of SARS-CoV-2 glycoprotein spike variants
Arruda, H. R. S., Lima, T. M., Alvim, R. G. F., Victorio, F. B. A., de Abreu, D. P. B., Marsili, F. F., Cruz, K. D., Marques, M. A., Sosa‐Acosta, P., Quiñones‐Vega, M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105696 · Cited by 14
Network analysis uncovers the communication structure of SARS-CoV-2 spike protein identifying sites for immunogen design
Manrique, P. D., Chakraborty, S., Henderson, R. C., Edwards, R. J., Mansbach, R. A., Nguyen, K., Stalls, V., Saunders, C., Mansouri, K., Acharya, P., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105855 · Cited by 13
Factor Xa cleaves SARS-CoV-2 spike protein to block viral entry and infection
Dong, W., Wang, J., Tian, L., Zhang, J., Settles, E. W., Qin, C., Kollath, D. R., Itogawa, A. N., Celona, K. R., Yi, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37336-9 · Cited by 13
Rapid genomic surveillance of SARS-CoV-2 in a dense urban community using environmental (sewage) samplesPreprint
Napit, R., Manandhar, P., Chaudhary, A., Shrestha, B., Poudel, A., Raut, R., Pradhan, S. M., Raut, S., Mathema, S., Rajbhandari, R. M., et al. (2021) · medRxiv · doi:10.1101/2021.03.29.21254053 · Cited by 13
Would It Be Possible to Stabilize Prefusion SARS-COV-2 Spikes with Ligands?Preprint
Lorenzo, M. M., Blasco, R., & Coll, J. M. (2021) · ChemRxiv · doi:10.26434/chemrxiv.13453919.v2 · Cited by 17
The furin cleavage site is required for pathogenesis, but not transmission, of SARS-CoV-2
Morgan, A. L., Vu, M. N., Zhou, Y., Lokugamage, K. G., Meyers, W. M., Alvarado, R. E., Ahearn, Y. P., Estes, L. K., Plante, J. A., Johnson, B. A., et al. (2025) · Journal of Virology · doi:10.1128/jvi.00467-25 · Cited by 13
Self-citation
Circular intensity differential scattering of light to characterize the coronavirus particles
Ashraf, M. W., Ranjan, R., & Diaspro, A. (2021) · Journal of the Optical Society of America B · doi:10.1364/josab.422646 · Cited by 12
Predominance of SARS-CoV-2 P.1 (Gamma) lineage inducing the recent COVID-19 wave in southern Brazil and the finding of an additional S: D614A mutation
Demoliner, M., da Silva, M. S., Gularte, J. S., Hansen, A. W., de Almeida, P. R., Weber, M. N., Heldt, F. H., Silveira, F., Filippi, M., Pereira, V. M. D. A. G., et al. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.105134 · Cited by 12
The Impact of COVID-19 Pandemic on Seafood Safety and Human Health
Rathod, N. B., Abed, N. E., Özoğul, F., Regenstein, J. M., Galanakis, C. M., Aljaloud, S. O., & Ibrahim, S. A. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.875164 · Cited by 12
Analysis of research hotspots in COVID-19 genomics based on citespace software: Bibliometric analysis
Pang, X., Peng, Z. Y., Zheng, X., Shi, J. J., & Zhou, B. C. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1060031 · Cited by 13
Longitudinal Trends in Cardiovascular Risk Factor Profiles and Complications Among Patients Hospitalized for COVID-19 Infection: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry
Hall, E. J., Ayers, C. R., Kolkailah, A. A., Rutan, C. M., Walchok, J. G., Williams, J. H., Wang, T. Y., Rodríguez, F., Bradley, S. M., Stevens, L. M., et al. (2023) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.122.009652 · Cited by 11
Impact of vaccination and variants of concern on long COVID clinical phenotypes
Kenny, G., McCann, K., O’Brien, C., O’Broin, C., Tinago, W., Yousif, O., O’Gorman, T., Cotter, A. G., Lambert, J. S., Feeney, E. R., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08783-y · Cited by 12
SARS-CoV-2 genomics and impact on clinical care for COVID-19
Lorenzo-Redondo, R., Carvalho, A. M. D. S., Hultquist, J. F., & Ozer, E. A. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad309 · Cited by 12
Evolutionary trajectory of diverse SARS-CoV-2 variants at the beginning of COVID-19 outbreak
Lv, J.-X., Liu, X., Pei, Y.-Y., Song, Z.-G., Chen, X., Hu, S.-J., She, J., Liu, Y., Chen, Y.-M., & Zhang, Y.-Z. (2024) · Virus Evolution · doi:10.1093/ve/veae020 · Cited by 16
Self-citation
Cell type-specific adaptation of the SARS-CoV-2 spike
Carrascosa-Sàez, M., Marqués, M.-C., IBV-Covid19-Pipeline, T., Geller, R., Elena, S. F., Rahmeh, A., Dufloo, J., & Sanjuán, R. (2024) · Virus Evolution · doi:10.1093/ve/veae032 · Cited by 13
Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission
Benlarbi, M., Ding, S., Bélanger, É., Tauzin, A., Poujol, R., Medjahed, H., Ferri, O. E., Bo, Y., Bourassa, C., Hussin, J., et al. (2024) · mBio · doi:10.1128/mbio.00907-24 · Cited by 12
Stages in COVID-19 vaccine development: The Nemesis, the Hubris and the Elpis
Nikhra, V. (2020) · International Journal of Clinical Virology · doi:10.29328/journal.ijcv.1001028 · Cited by 12
Computational analysis of protein stability and allosteric interaction networks in distinct conformational forms of the SARS-CoV-2 spike D614G mutant: reconciling functional mechanisms through allosteric model of spike regulation
Verkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1933594 · Cited by 12
COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era
Volkan, E. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00353-4 · Cited by 12
Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage
Wang, K., Wu, J., XinZHANG, Zeng, Q., Zhang, N., Huang, W., Tang, S., Wang, Y., Kong, W., Wang, Y., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105196 · Cited by 12
No association between the SARS-CoV-2 variants and mortality rates in the Eastern Mediterranean Region
Omais, S., Kharroubi, S. A., & Zaraket, H. (2021) · Gene · doi:10.1016/j.gene.2021.145843 · Cited by 13
Immune response variables and viral mutations impact on COVID-19 reinfection and relapse
Sanaie, S., Golipour, E., Shamekh, A., Sadaie, M. R., Mahmoodpoor, A., & Yousefi, M. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108108 · Cited by 12
SARS-CoV-2 variants, a still unfinished story
Pérez-Abeledo, M., & Moreno, J. C. S. (2021) · Vacunas (English Edition) · doi:10.1016/j.vacune.2021.10.003 · Cited by 12
Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy
Zhou, D., Zhou, R., & Chen, Z. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab027 · Cited by 12
SARS-CoV-2 Virology
Li, Y., & Li, J. Z. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.01.004 · Cited by 14
A hypothesis on designing strategy of effective RdRp inhibitors for the treatment of SARS-CoV-2
Chaube, U., Patel, B., & Bhatt, H. (2022) · 3 Biotech · doi:10.1007/s13205-022-03430-w · Cited by 12
SARS-CoV-2 infection dysregulates the expression of clinically relevant drug metabolizing enzymes in Vero E6 cells and membrane transporters in human lung tissues
Nwabufo, C. K., Hoque, M. T., Yip, L., Khara, M., Mubareka, S., Pollanen, M. S., & Bendayan, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1124693 · Cited by 13
ACoRE: Accurate SARS-CoV-2 genome reconstruction for the characterization of intra-host and inter-host viral diversity in clinical samples and for the evaluation of re-infections
Marcolungo, L., Beltrami, C., Esposti, C. D., Lopatriello, G., Piubelli, C., Mori, A., Pomari, E., Deiana, M., Scarso, S., Bisoffi, Z., et al. (2021) · Genomics · doi:10.1016/j.ygeno.2021.04.008 · Cited by 13
Mathematical modelling of the second wave of COVID-19 infections using deterministic and stochastic SIDR models
Lobato, F. S., Libotte, G. B., & Platt, G. M. (2021) · Nonlinear Dynamics · doi:10.1007/s11071-021-06680-0 · Cited by 13
Mutation in a SARS-CoV-2 Haplotype from Sub-Antarctic Chile Reveals New Insights into the Spike’s Dynamics
González-Puelma, J., Aldridge, J., de, M. M., Pinto, M., Uribe-Paredes, R., Fernández-Goycoolea, J., Álvarez-Saravia, D., Álvarez, H., Encina, G., Weitzel, T., et al. (2021) · Viruses · doi:10.3390/v13050883 · Cited by 12
SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
Duerr, R., Crosse, K. M., Valero-Jimenez, A. M., & Dittmann, M. (2021) · Microorganisms · doi:10.3390/microorganisms9071389 · Cited by 12

Authors: Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., Mirchandani, D., Scharton, D., Bilello, J. P., Ku, Z., An, Z., Kalveram, B., Freiberg, A. N., Menachery, V. D., Xie, X., Plante, K. S., Weaver, S. C., & Shi, P.-Y.
Affiliations: The University of Texas Medical Branch at Galveston (US)
Gilead Sciences (United States) (US)
Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
Corresponding author: Xie, Xuping
Plante, Kenneth S.
Weaver, Scott C.
Shi, Pei-Yong
ORCID: Plante, Jessica A.
Liu, Jianying
Xia, Hongjie
Johnson, Bryan A.
Zhang, Xianwen
Zou, Jing
Fontes-Garfias, Camila R.
Scharton, Dionna
Bilello, John P.
Ku, Zhiqiang
An, Zhiqiang
Freiberg, Alexander N.
Menachery, Vineet D.
Xie, Xuping
Plante, Kenneth S.
Weaver, Scott C.
Shi, Pei-Yong
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2020-10-26
Volume: 592
Issue: 7852
Pages: 116-121
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-020-2895-3
PMC: PMC8158177
OpenAlex: W3093768302
Cited by: 1,558
References: 37
Citations by year: 2026: 37 · 2025: 73 · 2024: 120 · 2023: 174 · 2022: 427 · 2021: 670 · 2020: 55
FWCI: 43.60
Type: journal article
Language: en
Update notices: correction (2021-06-15)
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
PubMed Central (submittedVersion, cc-by-nc-nd)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Amon G. Carter Foundation
John S. Dunn Foundation (AI145617)
University of Texas System
Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation (AI134907)
National Institutes of Health (AG049042, TL1TR001440, AI145617, AI142759, UL1TR001439)
National Institute on Aging (AI142759, AG049042, R00AG049092)
National Institute of Allergy and Infectious Diseases (R43AI145617, AI142759, R24AI120942, R01AI134907, R21AI145400, U01AI151801, U19AI142759, R01AI153602, AI153602, AG049042, AI134907, AI145617, UC7AI094660)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: SARS-CoV-2, viral fitness, viral replication, upper respiratory tract infection, virus transmission, neutralizing antibodies, vaccine efficacy, hamster model, lung epithelial cells, therapeutic antibodies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Spike mutation D614G alters SARS-CoV-2 fitness

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks